No profile data available.
Cyclerion Therapeutics, Inc. (CYCN) is a healthcare company in the urinary system treatment drugs industry, based in Cambridge, United States, with about 1 full-time employees.
It reported revenue of $2.07 million for fiscal year 2025, up 3.7% from fiscal year 2024, and net income of -$3.53 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0, down 100.0% from a year before. Its largest business segment, License Agreement, brought in 88% of segment revenue in fiscal year 2024. Its market capitalization was $15.73 million as of September 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of September 8, 2026.
, a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.
Cyclerion Therapeutics reported $2.07 million in revenue for fiscal year 2025, up 3.7% from $2.00 million in fiscal year 2024. In Q1 2026 revenue was $0.
License Agreement, with $1.75 million or 88% of segment revenue in fiscal year 2024. Next: License (13%).
$15.73 million as of September 8, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Akebia Therapeutics, Inc. (AKBA), Jyong Biotech Ltd. (MENS), Unicycive Therapeutics, Inc. (UNCY), Tvardi Therapeutics, Inc. (TVRD).